RT null
T1 Pegylated interferon plus ribavirin in HIV-infected patients with recurrent hepatitis C after liver transplantation: A prospective cohort study (vol 62, pg 92, 2015)
A1 Castells, Lluis
A1 Rimola, Antoni
A1 Manzardo, Christian
A1 Valdivieso, Andres
A1 Luis Montero, Jose
A1 Barcena, Rafael
A1 Abradelo, Manuel
A1 Xiol, Xavier
A1 Aguilera, Victoria
A1 Salcedo, Magdalena
A1 Rodriguez, Manuel
A1 Bernal, Carmen
A1 Suarez, Francisco
A1 Antela, Antonio
A1 Olivares, Sergio
A1 del Campo, Santos
A1 Laguno, Montserrat
A1 Fernandez, Jose R.
A1 de la Rosa, Gloria
A1 Agueero, Fernando
A1 Perez, Inaki
A1 Gonzalez-Garcia, Juan
A1 Esteban-Mur, Juan I.
A1 Miro, Jose M.
K1 Antiviral treatment
K1 HCV infection
K1 HIV infection
K1 Liver transplantation
K1 Pegylated-interferon
K1 Recurrence of hepatitis C
K1 Ribavirin; Survival
AB Background & aims: The aim of this study was to evaluate the results of treatment with pegylated interferon and ribavirin for the recurrence of hepatitis C after liver transplantation in HCV/HIV-coinfected patients.Methods: This was a prospective, multicentre cohort study, including 78 HCV/HIV-coinfected liver transplant patients who received treatment for recurrent hepatitis C. For comparison, we included 176 matched HCV-monoinfected patients who underwent liver transplantation during the same period of time at the same centres and were treated for recurrent hepatitis C.Results: Antiviral therapy was discontinued prematurely in 56% and 39% (p = 0.016), mainly because of toxicity (22% and 11%, respectively; p=0.034). Sustained virological response (SVR) was achieved in 21% of the coinfected patients and in 36% of monoinfected patients (p = 0.013). For genotype 1, SVR rates were 10% and 33% (p = 0.002), respectively; no significant differences were observed for the other genotypes. A multivariate analysis based on the whole series identified HIV-coinfection as an independent predictor of lack of SVR (OR, 0.17; 95% CI, 0.06-0.42). Other predictors of SVR were donor age, pretreatment HCV viral load, HCV genotype, and early virological response. SVR was associated with a significant improvement in survival: 5-year survival after antiviral treatment was 79% for HCV/HIV-coinfected patients with SVR vs. 43% for those without (p = 0.02) and 92% vs. 60% in HCV-monoinfected patients (p < 0.001), respectively.Conclusions: The response to pegylated interferon and ribavirin was poorer in HCV/HIV-coinfected liver recipients, particularly those with genotype 1. However, when SVR was achieved, survival of coinfected patients increased significantly.
PB Elsevier
SN 0168-8278
YR 2016
FD 2016-03-01
LK http://hdl.handle.net/10668/18823
UL http://hdl.handle.net/10668/18823
LA en
NO Castells L, Rimola A, Manzardo C, Valdivieso A, Montero JL, Barcena R, et al.  Pegylated interferon plus ribavirin in HIV-infected patients with recurrent hepatitis C after liver transplantation: a prospective cohort study. J Hepatol. 2015 Jan;62(1):92-100
DS RISalud
RD Apr 12, 2025